Quantum-Si incorporated
NASDAQ:QSIBiotechnology
+$0.05 today
- Market cap
- $213.79M
- Beta
- 3.17
- P/E (TTM)
- -2.1
- EPS (TTM)
- -$0.48
Volume 10.47M
Average 5.64M
QSI Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Quantum-Si incorporatedNASDAQ: QSI
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $1.23M rose 33.6% year over year, ahead of the +6.9% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 4.4% from the prior quarter. Over 3 fiscal years it compounded at +19.9% a year.
Context
- Depreciation & amortization amounted to 182.8% of revenue in FY2025, up 32.4 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +33.6% holds above the trailing-twelve-month pace of +6.9%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 4.45M USD
- Year-over-year change
- -3.2%
- 4-year CAGR
- +43.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 4.45M | -3.2% |
| FY2024 | 2024-12-31 | 4.6M | +10.7% |
| FY2023 | 2023-12-31 | 4.16M | +60.8% |
| FY2022 | 2022-12-31 | 2.58M | +148.2% |
| FY2021 | 2021-12-31 | 1.04M | — |
Depreciation & Amortization vs competitors
How QSI compares with its peers on the latest reported figures
- QSI's LTM Mar 2026 depreciation & amortization of $4.76M is the 4th highest of the 11 companies compared; the peer median is $1.41M.
- Its year-over-year change of +6.9% is the 5th highest of 10, against a peer median of +1.0%.
- Depreciation & amortization amounts to 257.1% of revenue for QSI, versus a peer median of 14.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $13M | +24.1% | +9.8% | 14.0% | |
| LTM Mar 2026 | $12.36M | +53.3% | -27.5% | — | |
| LTM Mar 2026 | $10.18M | +1.0% | +20.7% | — | |
| LTM Mar 2026 | $4.76M | +6.9% | +19.9% | 257.1% | |
| LTM Mar 2026 | $3.06M | +36.2% | +7.2% | — | |
| LTM Mar 2026 | $1.62M | -35.9% | -12.1% | — | |
| LTM Mar 2026 | $1.19M | -63.3% | -7.7% | 1.5% | |
| LTM Mar 2026 | $1.13M | -6.8% | -1.4% | — | |
ENGNenGene Holdings Inc. | LTM Apr 2026 | $670K | +79.6% | +28.8% | — |
LBRXLB Pharmaceuticals Inc Common Stock | LTM Mar 2026 | $325.5K | — | +443.4% | — |
| LTM Mar 2026 | $106K | -33.8% | -39.0% | 294.4% | |
| Peer median (excluding QSI) | $1.41M | +1.0% | +2.9% | 14.0% | |
Competitors are the stored peer set for QSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.08M | 3.06M | 2.44M |
| Cost of Revenue | 0 | 0 | 594K | 1.46M | 1.28M |
| Gross Profit | 0 | 0 | 488K | 1.6M | 1.15M |
| Gross Margin | — | — | 45.1% | 52.3% | 47.3% |
| Research & Development | 46.58M | 72.06M | 67.03M | 59.64M | 53.76M |
| Selling, General & Admin | 50.33M | 42.3M | 44.63M | 50.54M | 44.75M |
| Operating Expenses | 96.91M | 123.84M | 111.66M | 110.18M | 98.51M |
| Depreciation & Amortization | 1.04M | 2.58M | 4.16M | 4.6M | 4.45M |
| EBITDA | (93.94M) | (111.77M) | (91.8M) | (96.35M) | (96.83M) |
| EBITDA Margin | — | — | -8484.7% | -3150.8% | -3974.8% |
| Operating Income | (96.91M) | (123.84M) | (111.17M) | (108.58M) | (97.36M) |
| Operating Margin | — | — | -10274.6% | -3550.6% | -3996.7% |
| Interest Income | 0 | 0 | 0 | 0 | 8.96M |
| Interest Expense | 5K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 1.92M | (8.6M) | 15.21M | 7.63M | (3.92M) |
| Income Before Tax | (94.99M) | (132.44M) | (95.96M) | (100.95M) | (101.28M) |
| Pre-Tax Margin | — | — | -8868.8% | -3301.2% | -4157.7% |
| Income Tax Expense | 0 | 0 | 0 | 56K | 58K |
| Net Income | (94.99M) | (132.44M) | (95.96M) | (101.01M) | (101.34M) |
| Net Margin | — | — | -8868.8% | -3303.0% | -4160.1% |
| EPS (Basic) | (1.19) | (0.95) | (0.68) | (0.71) | (0.51) |
| EPS (Diluted) | (1.19) | (0.95) | (0.68) | (0.71) | (0.51) |
| Weighted Avg Shares | 79.58M | 139.26M | 141.3M | 143.2M | 197.77M |
| Weighted Avg Shares (Diluted) | 79.58M | 139.26M | 141.3M | 143.2M | 197.77M |
Quantum-Si incorporated
NASDAQ:QSI
Intrinsic Alpha fair value
Locked
Current Price
$1.07
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.